Assembly Biosciences Surpasses Q2 EPS Estimates with Significant Revenue Grow
Thursday, 8 August 2024, 22:29
Assembly Biosciences Q2 2023 Financial Overview
Assembly Biosciences (ASMB) has achieved noteworthy results in its second quarter of 2023. The company reported a GAAP EPS of - -1.98, which surpassed analyst estimates by $0.25. Additionally, revenue generated from collaborative research has reached $8.5 million.
Key Highlights
- Q2 GAAP EPS of -1.98 beats estimates by $0.25
- Collaborative research revenue amounts to $8.5 million
This performance not only reflects the company's resilience but also opens doors for potential growth in upcoming quarters as it leverages its research pipeline.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.